MedPath

An 8 week randomised, double-blind, placebo controlled trial investigating the role of adjunctive bioactive lipids specifically; docosahexaenoic acid (DHA) versus eicosapentaenoic acid (EPA) in Major Depressive Disorder - with a 6 week open label extension of DHA in patients aged 18-65years.

Phase 4
Conditions
Major Depression
Mental Health - Depression
Registration Number
ACTRN12610000710022
Lead Sponsor
The Melbourne Clinic
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot yet recruiting
Sex
All
Target Recruitment
90
Inclusion Criteria

diagnosis of major depressive episode

Exclusion Criteria

other serious mental or neurological illness

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath